Market LIVE
Published markets; coverage varies by country
Product profile · United States

SOVALDI

 ·  Patent Litigation & Settlement History ↓

IngredientSOFOSBUVIR
Application typeNDA
Application204671
Product001
Dosage formTABLET
RouteORAL
Strength400MG
Approval date2013-12-06
Marketing statusPrescription
Status event—
ApplicantGILEAD SCIENCES INC
Product source

Current GenericRadar decision

Year—
SelectionEXISTING_GENERIC
ReviewCOMPLETED
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2022-01-27
Status event—

Final ANDA candidate 211353/001 on 2022-01-27. Source-level RLD/TE screen; earliest Final and exact Product source reference require independent review.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
83342702028-03-21DS/DP/U U-1470———
———
85807652028-03-21DS/DP/U U-1470———
———
90855732028-03-21DS/DP/U U-1470———
———
83342702028-09-21— ————
—2028-09-21—
85807652028-09-21— ————
—2028-09-21—
90855732028-09-21— ————
—2028-09-21—
79645802029-03-26DS/DP/U U-1470———
———
86333092029-03-26DS/DP/U U-1470———
———
88891592029-03-26DP/U U-1470———
———
95499412029-03-26U U-1958———
———
79645802029-09-26— ————
—2029-09-26—
86333092029-09-26— ————
—2029-09-26—
88891592029-09-26— ————
—2029-09-26—
95499412029-09-26— ————
—2029-09-26—
92843422030-09-13DS/DP/U U-1470———
———
86180762030-12-11DS/DP/U U-1470———
———
92843422031-03-13— ————
—2031-03-13—
86180762031-06-11— ————
—2031-06-11—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
ODE*—2026-08-28————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
211353 / 001FINAL_APPROVAL · FINAL_APPROVED2022-01-27—TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 1 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
211353 / 001TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2022-01-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.